id,disease_progression_status,survival_status,clinical_response_rate_target_lasion,clinical_response_rate_non_target_lasion,clinical_response_rate_new_lasion,clinical_response_rate_result,radiological_response_rate_target_lasion,radiological_response_rate_non_target_lasion,radiological_response_rate_new_lasion,radiological_response_rate_result,pathological_response_rate_target_lasion,pathological_response_rate_non_target_lasion,pathological_response_rate_new_lasion,pathological_response_rate_result,time,registration_number,laterality,current_chemo_protocol,chemo_starting_date,chemo_cycle_no,chemo_detail,disease_progression_status_date,pfs,survival_status_date,overall_survival,clinical_response_rate_date,radiological_response_rate_date,pathological_response_rate_date,cancer_type,patient_id_id,patient_id_socio_economic_status_name,patient_id_unique_id,patient_id_name,patient_id_phone,patient_id_date_of_birth,patient_id_gender,patient_id_blood_group,patient_id_area,patient_id_police_station,patient_id_district,doctor_id_name,center_id_name,grade_name,line_of_treatment_name,diagnosis_disease_group_name,diagnosis_subgroup_diagnosis_disease_group_name,diagnosis_subgroup_name,diagnosis_primary_site_name,diagnosis_laterility_name,patient_id_socio_economic_status,grade,disease_progression_status_name,survival_status_name,clinical_response_rate_target_lasion_name,clinical_response_rate_non_target_lasion_name,clinical_response_rate_new_lasion_name,clinical_response_rate_result_name,radiological_response_rate_target_lasion_name,radiological_response_rate_non_target_lasion_name,radiological_response_rate_new_lasion_name,radiological_response_rate_result_name,diagnosis_laterility,line_of_treatment,diagnosis_subgroup,pathological_response_rate_target_lasion_name,pathological_response_rate_non_target_lasion_name,pathological_response_rate_new_lasion_name,pathological_response_rate_result_name,diagnosis_disease_group,diagnosis_primary_site,name,value,unit,date,patient_observation_id
20,,,,,,,,,,,,,,,2024-04-30T17:06:21+06:00,BSH - H12007097481,,Tucatinib + Capecitabine,2024-01-06,,"Started TCPH, C1 started from 19.09.2020, C6 completed on 2.01.2021
Reviewed from Apollo India by Prof T Raja, New brain lesions (WBRT completed) and Kadcyla 3rd line
Antibody started, C1 from 27.03.2021, Cycle 15 due on 22.01.22 (Delayed due to covid and received on
5.02.22)> C18 received 9.04.2022> MRM done on 5.05.22> Adv to continue Kadcyla, C19 started from
28.05.22> C32 completed on 18.03.2023 > PD in brain (leptomeningeal spread)
Started ChT with Tab Capecitabine + Tab Lapatinib will start from 30.04.2023 (INDIA), Hold since
Sep 30 due to raised LFTs> Restarted from 12 NOV 23 .Due to PD> Started Tucatinib + Capecitabine from 6 Jan 2024",2024-01-06,,2014-01-10,,2024-01-06,,,Breast,17,Upper middle class,BSBSC-240000017,SK. FARZANA RAHMAN,1755632361,1984-01-05,Female,,,,,Dr Md Arifur Rahman,BSH,2.0,4th Line,C50- Malignant neoplasm of breast,C50- Malignant neoplasm of breast,"C50.9- Breast, unspecified",Breast,Right,,,Progressed,Alive,PD,PD,No,PD,CR,,,,,,,,,,,,,,,,,
